hackint0sh/New-Dataset huggingface dataset:
To address these pressing diagnostic and monitoring needs in NSCLC-LM management, the investigator proposes a forward-looking, non-interventional clinical study harnessing the power of cutting-edge proteomic technologies. These platforms, characterized by their high throughput, exquisite sensitivity, and minimal sample volume requirements, offer a promising avenue for elucidating the intricacies of chemotherapy response in intrathecal therapy. The study aims to provide valuable insights into improving diagnostic accuracy for LM in NSCLC patients and to establish a more rigorous framework for assessing treatment efficacy in individuals undergoing intrathecal chemotherapy, ultimately contributing to enhanced patient care and personalized therapeutic strategies. conditions: Diagnosis studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 60 type: ESTIMATED name: Pemetrexed measure: Progression-free survival (PFS) measure: Overall survival (OS) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Union hospital city: Wuhan state: Hubei zip: 430000 country: China lat: 30.58333 lon: 114.26667 hasResults: False
nctId: NCT06346964 id: 2024-341 briefTitle: Self-Care Management in Older Adults overallStatus: NOT_YET_RECRUITING date: 2024-04-22 date: 2025-04-22 date: 2025-06-30 date: 2024-04-04 date: 2024-04-04 name: Ankara Yildirim Beyazıt University class: OTHER briefSummary: Self-management of chronic diseases requires the ability to manage the symptoms, treatment, and lifestyle changes inherent in living with a chronic disease. Rational drug use by older adults is of particular importance. Mobile applications are being developed to facilitate the compliance of older adults with chronic diseases with medication treatment and to increase their disease self-management skills. The research was planned to strengthen participation in social life through rational drug use and disease self-care management in older adults with chronic diseases. The research will be conducted in a parallel group randomized controlled manner. In the research, a mobile application will be developed for the use of older adults. Older adults will be asked to use the mobile application for at least 6 months, and the scales will be re-administered face to face or online in the 3rd and 6th months of the intervention. conditions: Disease Self Management studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 72 type: ESTIMATED name: mobile application measure: Participation in social life (Social Inclusion Scale) measure: Participation in social life (Social Inclusion Scale) measure: Participation in social life (Social Inclusion Scale) sex: ALL minimumAge: 60 Years maximumAge: 79 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ankara Yıldırım Beyazıt University city: Ankara state: Çubuk/Turkey zip: 06760 country: Turkey lat: 39.91987 lon: 32.85427 hasResults: False
nctId: NCT06346951 id: LPan briefTitle: Survey on the Current Status of IFD Diagnosis and Treatment by Intensive Care Physicians in Sichuan Province (IFS) acronym: IFS overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2024-09-30 date: 2024-09-30 date: 2024-04-04 date: 2024-04-04 name: Sichuan Provincial People's Hospital class: OTHER briefSummary: The goal of this survey is to learn about the current status of the diagnosis and treatment of invasive fungal infections among intensive care physicians in Sichuan Province (IFS). Its primary focus lies on answering the following questions: ①awareness and proficiency in diagnosis and treatment; ②the use of antifungal medications; ③the application of microbiological identification and diagnostic methods. We aim to analyze the problems and deficiencies that existed among intensive care physicians in order to provide a basis for the development of targeted training and intervention measures. conditions: Invasive Fungal Infections studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 300 type: ESTIMATED measure: The survey on the hospital's diagnostic and treatment standards and infrastructure for invasive fungal infections measure: The survey on the awareness of an invasive fungal infection among intensive care physicians sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06346938 id: 2024WHXH001 briefTitle: The Clinical Significance of CT-based Biomarkers in the Classification and Prognosis of Bronchiectasis overallStatus: NOT_YET_RECRUITING date: 2024-03-26 date: 2027-03-26 date: 2027-03-26 date: 2024-04-04 date: 2024-04-04 name: Wuhan Union Hospital, China class: OTHER briefSummary: As the third major chronic airway disease in China, bronchiectasis has a wide range of patients. However, the involved sites, morphological features and airway obstruction of bronchiectasis are varied, and clinical heterogeneity is high, making prognosis and severity difficult to evaluate. CT plays an important role in the diagnosis and classification of ramadasis. Based on this, we analyzed the CT findings of patients with bronchiectasis and followed up patients with bronchiectasis to understand their disease progression and prognosis, so as to further analyze the role of CT biomarkers in the type and prognosis of bronchiectasis diseases. conditions: Bronchiectasis studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 300 type: ESTIMATED measure: Frequency of acute exacerbations of bronchiectasis measure: Deterioration of lung function measure: Severity of dyspnoea measure: Degree of emphysema measure: Mucus plug score measure: Bhalla scores on CT of participants' lungs measure: Frequency of hospitalisation measure: Death sex: ALL minimumAge: 18 Years maximumAge: 100 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Wuhan Union Hospital city: Wuhan state: Hubei zip: 430022 country: China name: Xiaorong Wang role: CONTACT phone: 18627195231 phoneExt: +86 email: rong-100@163.com lat: 30.58333 lon: 114.26667 hasResults: False
nctId: NCT06346925 id: SHR8735-116 briefTitle: Study of the Food Effects of Herombopag Olamine Tablets in Healthy Subjects. overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2024-07 date: 2024-07 date: 2024-04-04 date: 2024-04-04 name: Jiangsu HengRui Medicine Co., Ltd. class: INDUSTRY briefSummary: This study was designed as a single-center, randomized, open, two-cycle, cross-over trial. It is planned to enroll 18 healthy subjects conditions: Adult Patients With Chronic Primary ITP conditions: Adult Patients With SAA Who do Not Respond Well to Immunosuppressive Therapy studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: TREATMENT masking: NONE count: 18 type: ESTIMATED name: Herombopag Olamine Tablets measure: Cmax measure: AUC0-t measure: AUC0-∞ measure: Tmax measure: t1/2 measure: CL/F measure: V/F measure: Incidence and severity of adverse events (AEs) sex: ALL minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT facility: The Second Hospital of Anhui Medical Uniersity city: Hefei state: Anhui zip: 230601 country: China name: Wei Hu role: PRINCIPAL_INVESTIGATOR lat: 31.86389 lon: 117.28083 hasResults: False
nctId: NCT06346912 id: TXB2023022 briefTitle: CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL overallStatus: NOT_YET_RECRUITING date: 2024-04-15 date: 2027-04-15 date: 2027-04-15 date: 2024-04-04 date: 2024-04-04 name: Zhejiang University class: OTHER name: Shanghai YaKe Biotechnology Ltd. briefSummary: Clinical Trial for the safety and efficacy of CD19-BAFF CAR-T cells therapy for refractory/relapsed B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma. conditions: Acute Lymphoblastic Leukemia,B-Cell conditions: Non-hodgkin Lymphoma,B Cell studyType: INTERVENTIONAL phases: EARLY_PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 20 type: ESTIMATED name: CD19-BAFF Targeted CAR T-cells measure: Dose-limiting toxicity (DLT) measure: Incidence of treatment-emergent adverse events (TEAEs) measure: Overall response rate ,ORR measure: Duration of remission ,DOR measure: Event-free survival, EFS measure: Overall survival, OS sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: The first affiliated hospital of medical college of zhejiang university city: Hangzhou state: Zhejiang zip: 310000 country: China name: He Huang, MD role: CONTACT phone: 86-13605714822 email: hehuangyu@126.com name: Yongxian Hu, MD role: CONTACT phone: +8615957162012 email: huyongxian2000@aliyun.com lat: 30.29365 lon: 120.16142 hasResults: False
nctId: NCT06346899 id: TAK-743-4012 briefTitle: A Study of Lanadelumab (Takhzyro) and Icatibant (Firazyr®) in Persons With HAE in China overallStatus: NOT_YET_RECRUITING date: 2024-08-14 date: 2025-08-13 date: 2025-08-13 date: 2024-04-04 date: 2024-04-04 name: Takeda class: INDUSTRY briefSummary: The Chinese health authority has approved lanadelumab to prevent Hereditary Angioedema (HAE) attacks in persons of 12 years and older. It has also approved icatibant to treat acute HAE attacks in persons 2 years and older.
One of the main aims of this study is to learn about the number of HAE attacks in 1 month in Chinese persons with HAE during their treatment with lanadelumab. The other main aim is to learn how much time is needed to resolve acute HAE attacks when treated with icatibant. Other aims of this study are to learn more about side effects of lanadelumab and icatibant treatment as well as to collect additional information on the treatment with lanadelumab, such as the dose and how often it needs to be given, reasons for stopping the treatment with lanadelumab and how long it was taken until stopping. Participants will be treated by their doctors according to routine medical practice. Only data already available in the medical records of the participants will be reviewed and collected during this study. conditions: Hereditary Angioedema (HAE) studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 130 type: ESTIMATED name: No intervention measure: Monthly Rate of HAE Attacks for Each Lanadelumab-treated Participant During the Lanadelumab Exposure Period measure: Median Time to Complete Attack Resolution for Icatibant Treated Participants measure: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) During Lanadelumab and Icatibant Exposure Period measure: Dosage of Lanadelumab Among Lanadelumab-treated Participant During the Lanadelumab Exposure Period measure: Frequency Administration of Lanadelumab Among Lanadelumab-treated Participant During the Lanadelumab Exposure Period measure: Number of Participants with Reasons of Discontinuation of Lanadelumab During the Lanadelumab Exposure Period measure: Time to Lanadelumab Discontinuation Among Lanadelumab-treated Participant During the Lanadelumab Exposure Period sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06346886 id: 23-011703 briefTitle: HTN App for HTN Control and Cardiovascular Health Among African-Americans overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-07 date: 2025-07 date: 2024-04-04 date: 2024-04-04 name: Mayo Clinic class: OTHER name: Miami Heart Research Institute Inc. briefSummary: The purpose of this study is to test the hypertension (HTN) app-based intervention to see if it is more effective in improving uncontrolled HTN and HTN self-care among Africian-Americans from baseline to post-intervention (immediate, 3 months and 6 months post-intervention) as compared to the standard of care. conditions: Hypertension studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 100 type: ESTIMATED name: FAITH! HTN app measure: Absolute Change in Systolic Blood Pressure (BP) measure: HTN Self-Care as reported by H-SCALE(HTN Self-Care Activity Level Effects) measure: Proportion of subjects reaching BP control measure: Change in BP as assessed by home BP cuff measurements measure: CV Health Knowledge as measured by module assessment scores measure: Hypertension (HTN) Knowledge as assessed by 11-item questionnaire sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Mayo Clinic city: Rochester state: Minnesota zip: 55905 country: United States name: Lainey Moen role: CONTACT phone: 507-266-7062 email: Moen.Lainey@mayo.edu name: Ashton Krogman role: CONTACT phone: (507) 266-2087 email: Krogman.Ashton@mayo.edu name: LaPrincess Brewer, M.D., M.P.H. role: PRINCIPAL_INVESTIGATOR lat: 44.02163 lon: -92.4699 hasResults: False
nctId: NCT06346873 id: 23-008090 briefTitle: Demonstrating Efficacy of JOGO for the Treatment of Tremor overallStatus: NOT_YET_RECRUITING date: 2024-09 date: 2026-09 date: 2027-09 date: 2024-04-04 date: 2024-04-04 name: Mayo Clinic class: OTHER briefSummary: This research is being done to determine the effectiveness of a new treatment, called JOGO, for patients with functional tremor (FT). JOGO is a biofeedback device that has been shown to help patients with several conditions, e.g., chronic pain, migraine, and Parkinson's disease (PD)-related tremor. JOGO provides biofeedback by using wireless adhesive stickers, called surface electromyography, to get information about muscle activity. This information is then used to modify symptoms through a series of training sessions with a physical therapist and individual practice. conditions: Functional Neurological Disorder studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 30 type: ESTIMATED name: JOGO measure: Change in TETRAS scores 1 month measure: Change in TETRAS scores 2 months measure: Change in QUEST scores measure: Tremor prevalence measure: Tremor resolution 1 month measure: Tremor resolution 2 months measure: Change in BDI-II scores measure: Change in BAI scores measure: Change in Intolerance of Uncertainty Scale sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Mayo Clinic in Florida city: Jacksonville state: Florida zip: 32224 country: United States lat: 30.33218 lon: -81.65565 hasResults: False
nctId: NCT06346860 id: 09.2024.241 briefTitle: Comparing Intrathecal Morphine With Modified Thoracoabdominal Nerve Block Through Perichondral Approach in Major Abdominal Surgery overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-04 date: 2025-04 date: 2024-04-04 date: 2024-04-19 name: Marmara University class: OTHER briefSummary: Abdominal surgery causes severe postoperative pain due to retraction of the abdominal wall and direct manipulation of visceral organs. It leads to delayed postoperative recovery, increased postoperative morbidity and mortality. Intrathecal morphine, epidural analgesia and patient-controlled intravenous analgesia are used in postoperative pain management of abdominal surgeries. Intrathecal morphine is frequently used in many centers because it provides effective pain control. However; morphine has undesirable effects such as urinary retention, postoperative nausea and vomiting, and respiratory depression. Modified thoracoabdominal nerves block through perichondrial approach is a technique defined by the modification of the thoracoabdominal nerves block through perichondrial approach, in which local anesthetics are delivered only to the underside of the perichondral surface. The primary implication of this study is to compare postoperative pain scores and opioid consumption in patients undergoing major abdominal surgery with intrathecal morphine or modified thoracoabdominal nerves block through perichondrial approach. conditions: Opioid Use conditions: Postoperative Pain studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SCREENING masking: NONE count: 56 type: ESTIMATED name: Regional Block Comparison measure: Comparison of postoperative opioid consumption between two groups via Patient Controlled Analgesia (PCA) device measure: Postoperative pain assessment with Numeric Rating Scale (NRS) measure: Comparison of the frequency of treatment related complications measure: Participant satisfaction sex: ALL minimumAge: 18 Years maximumAge: 90 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Marmara University School of Medicine city: Istanbul country: Turkey name: Beliz Bilgili role: CONTACT phone: 05362187927 email: belizbilgili@gmail.com name: Ayse Deniz Kayir role: CONTACT phone: 05465626316 email: kayir_95@hotmail.com lat: 41.01384 lon: 28.94966 hasResults: False
nctId: NCT06346847 id: TAC/231001/AKM/IBS id: IBS-D PAM type: OTHER domain: The Akkermansia Company briefTitle: Study to Assess Effects of Pasteurized Akkermansia Muciniphila vs Placebo in Participants With Diarrhea-predominant IBS acronym: PAM-DIGEST overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2025-05-01 date: 2025-05-01 date: 2024-04-04 date: 2024-04-04 name: A-Mansia Biotech S.A. class: INDUSTRY name: Vedic Lifesciences Pvt. Ltd. briefSummary: The present study is a randomized, double-blind, placebo-controlled, parallel group clinical study that assesses the effect of pasteurized Akkermansia muciniphila on the complaints of subjects with moderate to severe diarrhoea-predominant irritable bowel syndrome (IBS-D). The trial is also evaluating the potential of pAkk on anxiety, low mood and stress of the participants, as well as its safety and tolerability.
nctId: NCT06346834 id: PRO-sIPV-4002 briefTitle: Sequential Vaccination of Poliomyelitis Vaccine (Vero Cells), Inactivated, Sabin Strains From Different Manufacturers overallStatus: NOT_YET_RECRUITING date: 2024-04-30 date: 2024-08-31 date: 2024-12-30 date: 2024-04-04 date: 2024-04-15 name: Sinovac Biotech Co., Ltd class: INDUSTRY briefSummary: To evaluate the immunogenicity and safety of sequential vaccination with Sinovac sIPV among infants who have received two doses of Biological Products Co., Ltd. sIPV. conditions: Poliomyelitis studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 200 type: ESTIMATED name: sIPV measure: Geometric Mean Increase (GMI) measure: Geometric Mean Titer (GMT) measure: Seropositivity rate measure: Seroconversion rate measure: Adverse reaction incidence measure: Serious adverse events incidence sex: ALL maximumAge: 12 Months stdAges: CHILD hasResults: False
nctId: NCT06346821 id: WestChinaGBMTTFieldsV1.0 briefTitle: Tumor Treating Fields for Newly Diagnosed Glioblastoma: Two Emulated Trials With Chinese Multi-Hospital Based Real-World Data overallStatus: RECRUITING date: 2023-07-04 date: 2024-04-01 date: 2024-05-01 date: 2024-04-04 date: 2024-04-04 name: Sichuan University class: OTHER briefSummary: The goal of this observational study is to learn about the effectiveness of Optune® (Tumor Treating Fields) in newly diagnosed glioblastoma (GBM) in China. The main question it aims to answer are:
* Concomitantly or adjuvantly receive TTFields. conditions: Glioblastoma Multiforme studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: CROSS_SECTIONAL count: 200 type: ESTIMATED name: Optune® (Tumor Treating Fields) measure: Overall Survival (OS) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: West China Hospital status: RECRUITING city: Chengdu state: Sichuan zip: 610041 country: China name: Lei Liu, PhD, MD role: CONTACT phone: +8618980606231 email: liuleihx@gmail.com lat: 30.66667 lon: 104.06667 hasResults: False
nctId: NCT06346808 id: PDAC-OV briefTitle: Oncolytic Virus Plus Anti-PD1 and Chemotherapy as Preoperative Therapy for Patients With BRPC/LAPC overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2026-05-01 date: 2027-05-01 date: 2024-04-04 date: 2024-04-04 name: Sichuan University class: OTHER briefSummary: The aim of this single center, single arm and prospective study is to explore the safety and efficacy of Oncolytic virus Plus Anti-PD1 and Chemotherapy as Preoperative therapy for Patients with Borderline Resectable and Locally Advanced Pancreatic Cancer conditions: Pancreatic Cancer studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 20 type: ESTIMATED name: Oncolytic virus Plus Anti-PD1 and Chemotherapy measure: Incidence of Treatment-Related Adverse Events [Safety and Tolerability] measure: R0 resection rate measure: ORR sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: West China Hospital, Sichuan University city: Chengdu state: Sichuan zip: 610000 country: China name: Zhong Wu, MD role: CONTACT lat: 30.66667 lon: 104.06667 hasResults: False
nctId: NCT06346795 id: SelcukC briefTitle: Class II Restorations With High-Filled Flowable Composites overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2024-12-01 date: 2025-06-01 date: 2024-04-04 date: 2024-04-25 name: Selcuk University class: OTHER briefSummary: In the study, Class II restorations will be performed with G-aenial Universal Injectable (GC/ Tokyo, Japan), Grandio Flow (VOCO/ Germany), and Clearfil Majesty Flow (Kuraray/ Japan) composites will evaluated. Restorations will be assessed according to modified USPHS criteria in 1st week, 6th months, and 12th months from the placement date. The Chi-square test will used for statistical analysis of the difference between the groups, and the Cochran Q test will used for the significance of the difference between time-dependent changes within each group (p\<0.05). conditions: Dental Caries conditions: Class II Dental Caries studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 60 type: ESTIMATED name: High-filling flowable dental composite measure: Retention measure: Color match measure: Marginal discoloration measure: Marginal adaptation measure: Secondary caries measure: Surface texture measure: Anatomical form measure: Postoperative sensitivity sex: ALL minimumAge: 18 Years maximumAge: 50 Years stdAges: ADULT facility: Selcuk University, Faculty of Dentistry, Restorative Dentistry Department city: Konya country: Turkey lat: 37.87135 lon: 32.48464 hasResults: False
nctId: NCT06346782 id: IRB00370545 briefTitle: Feasibility and Acceptability of Internet-based Parent-child Interaction Therapy (I-PCIT) in Pediatric Cancer acronym: I-PCIT overallStatus: RECRUITING date: 2024-02-19 date: 2028-08-01 date: 2028-08-01 date: 2024-04-04 date: 2024-04-04 name: Johns Hopkins All Children's Hospital class: OTHER briefSummary: This study is being done to learn whether a telehealth intervention called "Internet-Based Parent Child Interaction Therapy," or I-PCIT," can help parents improve the child's behavior if the child currently or previously went through cancer treatment.